Multidrug resistance consists of a series of genetic and epigenetic alternations that involve multifactorial and complex processes, which are a challenge to successful cancer treatments. Accompanied by advances in biotechnology and highdimensional data analysis techniques that are bringing in new opportunities in modeling biological systems with continuous phenotypic structured models, we study a cancer cell population model that considers a multi-dimensional continuous resistance trait to multiple drugs to investigate multidrug resistance.
Introduction
The biological mechanisms responsible for the emergence of drug resistance and its propagation often involve a multifactorial and complex process of genetic and epigenetic alternations [1] [2] [3] , that arise through a series of genetic and non-genetic changes [4] [5] [6] [7] . Such changes can be due to drug administration (drug induced resistance) [8, 9] , or they can emerge independent of therapy due to intrinsic mechanisms. Cancer cells may develop simultaneous resistance to structurally and mechanistically unrelated drugs, leading to multidrug resistance (MDR) [1, 2, 10] . The complex dynamical nature of MDR is one of the most challenging obstacles to successful treatment.
The complexity of the mechanisms underlying drug resistance has encouraged its study through mathematical modeling. Such models aim at providing quantitative tools for testing therapies that circumvent or at least delay the unfortunate consequences of drug resistance. Examples include the models of Goldie and Coldman [11] [12] [13] that are based on resistance due to point mutations. These works were proceeded by many studies considering stochastic models (including branching process and multiple mutations) to study MDR and optimal control of drug scheduling [14] [15] [16] [17] . Alternative approach includes continuum deterministic models using ordinary differential equations, for example, modeling kinetic resistance [18] and point mutations [19] , and partial differential equations, where spatial heterogeneity and vascularization can be readily incorporated [20] [21] [22] . For additional approaches see [17, [23] [24] [25] [26] [27] [28] .
In addition to the aforementioned modeling approaches, the advance of biotechnology in collecting data characterizing the phenotype is bringing in new opportunities of mathematical modeling of biological systems. The most recent technology allows cytometry data to be collected up to O(50) dimensions, Methylation profiles in the scale of O(1000), and gene-expression profile in the scale of O(10000) [29] [30] [31] [32] [33] [34] . In particular, recent advances in single cell RNA sequencing technologies has enabled a new high-dimensional definition of cell states, that is on the order of 20,000 protein encoding genes that compose the transcriptome [32, 35] . The high-dimensionality of the data makes it practically impossible to consider a meaningful model on the original space in which the data is collected. Thus, various dimension reduction techniques, such as, principal component analysis [36, 37] , t-distributed stochastic neighbor embedding [30, 38, 39] , diffusion maps [40, 41] , and machine learning techniques [42, 43] , have been employed to reduce the dimensionality and to identify only the critical directions. In contrast to classical biology and modeling approaches, where cell types are classified into discrete states and differentiation is considered as a stepwise process of binary branching decision, the new technologies and data analysis enabled considering cell differentiation as a continuous process that can be mapped into a continuum of cellular and molecular phenotypes [31, 33, 40] .
In other words, the high-dimensional configuration space is mapped into a continuous trait in a lower-dimensional space. Figure 1 shows two examples of high-dimensional cell data mapped into a continuous trait in a lower dimensional space using stochastic neighbor embedding (viSNE) [38] and diffusion mapping [41] . This reveals the continuous phenotypic trait space where resistance can be locally characterized. For instance, the left figure shows that relapsed leukemia cells are associated with high expression of CD34, and the ALDH1 in the right figure is related to cancerous stem cells in mammary gland and breast cancer [44] . This opens the door to mathematical models that assume a continuous trait space [45, 46] . Among continuous phenotypic structured models, recent studies in [47] [48] [49] [50] [51] [52] consider a continuous trait variable that represents the level of cytotoxic drug resistance. This framework allows to explicitly model the heterogeneous response to drugs and effectively study the selection dynamics under microenvironmental constraints and chemotherapy. The asymptotic distributions on the resistance trait space are obtained in [47] , and the following works in [49, 51] extend it to include mutations and epimutations. The distribution of resistance levels can be then translated to therapeutic recommendation. The effectiveness of a combination of cytotoxic and cytostatic drugs when cytotoxic resistance emerge is studied in [47] . An optimal combination therapy to eliminate the most resis- reproduced from the data provided in [38] and [41] . tant clones is proposed in [52] . Moreover, [52] extends the framework that was restricted to solid tumor that is radially symmetric with a fixed boundary [48] to an asymmetric tumor growth model with moving boundary. However, this framework is limited to a single trait variable to a cytotoxic drug.
In this paper we extend the framework of [52] to multi-dimensional resistance trait. We compare our approach that allows for a continuous drug response to more traditional approaches that assume a discrete response to drugs. The paper is organized as follows. In section 2, we introduce a mathematical model for MDR assuming continuous trait variables. We parameterize our model as an extension of a discrete resistance state model in section 2.1 and compute the maximal fitness trait of resistance in section 2.2 for different types of continuum models. This allows us to characterize the cases when the solutions of the continuous models are qualitatively different than the corresponding discrete models. Section 2.3 presents simulation results for the different cases of cytotoxic and cytostatic drugs studied in 2.2. The impact of mutations and epimutations is studied in section 2.4. In section 3 we simulate tumor growth and resistance dy-namics subject to MDR on different types of tumors characterized by turnover rates and the proliferating ratios. Our simulations correspond to the discrete MDR models studied by Komarova and Wodarz (2005) [53] and Gardner (2002) [54] . We observe that a combination therapy with multiple cytotoxic drugs is also effective in high turnover tumors using relatively high dosages. Increasing the dosage in low turnover tumor is effective only for certain drug uptake functions. In addition, the drug response function plays a key role in determining the tumor growth dynamics when combination therapy is administered using cellcycle nonspecific cytotoxic drugs, such as Cyclophosphamide and Doxorubicin.
Conclusions and future directions are discussed in section 4.
Models of multidrug resistance
Let us consider a cancer growth model under multidrug therapy that de-
resistance level to the i-th drug or the i-th drug mechanism, where θ i = 0 and θ i = 1 represents the fully-sensitive cells and fully-resistant cells to drug i, respectively. The value of θ i can be obtained by normalizing the expression level of a gene or a gene cluster that is linked to the cellular levels of drug resistance and proliferative potential, such as ALDH1, CD44, CD117, or MDR1 [38, [55] [56] [57] . The governing equations follows the dynamics of the density of proliferating cells, n P = n P (t, θ), and quiescent cells, n Q = n Q (t, θ), as
The first term on the RHS of Eq. (1) is a growth term, R(t, θ), which we assume depends on the resource level s 0 (t) with the proliferation rate function ϕ(θ) as R(t, θ) = ϕ(θ)s 0 (t). Also, we assume an exponential growth by considering a constant apoptosis rate D for the proliferating cells and D Q for the quiescent cells. To consider a logistic growth, we substitute both terms with a densitydependent apoptosis term dρ(t), where ρ(t) is the total number of cells
and d is a constant that determines the cell capacity.
The net effects of the cytotoxic drugs on the proliferating and quiescent cells are denoted as C P (t, θ) and C Q (t, θ), respectively. These terms depend on the marginal drug effects, C i = C i (t, θ; c i (t)), the cell death rate due to the i-th drug, which is assumed to be a function of the drug concentration c i (t). We
, where µ i (θ) is the drug uptake function of the i-th drug, or the exponential kill model [54] ,
where C i represents the probability of the cell death due to the i-th drug. The net drug effect is modeled as C P (t, θ) = Φ(C 1 , ..., C M ), where Φ is the overall drug effect function that can be taken for the cytotoxic drugs as
and similarly for C Q . The form (3) is valid when C i is the probability of death due to the i-th drug (C i ≤ 1), and assuming that the drug effects are independent. Dependency between the drugs can be imposed through different choices of Φ, e.g., Copula functions [58] that are used to describe the dependence between random variables using multivariate probability distributions with prescribed marginal distribution functions. In addition to the cytotoxic drugs, we consider cytostatic drugs, which we assume delay the proliferation according to
The net cytostatic drug effect delays the progression of the proliferating cells through the cell cycle. We assume an additive Φ:
Proliferating cells enter the quiescent state at a rate q and quiescent cells return to the cycling compartment at a rate p. These rates regulate the proliferating portion δ(t) . = n P dθ/ρ(t). To balance a fixed ratio of proliferating cells, namely the proliferating index δ * , the transfer rate q can be computed as
The last term in Eq. (1) is a mutation term. We assume that mutations occur at a rate w during the proliferation cycle. The mutation is modeled as a integral term with a kernel function M (θ, ϑ). M (θ, ϑ) represents the probability of a mother trait ϑ mutating to a daughter trait θ that is taken as an asymmetric exponential function with mutation range , i.e.,
for θ ≥ ϑ, and zero otherwise. Here, M 0 is a normalizing constant. This model represents a mutation that gradually increases the resistance level through multiple mutations. A rare mutation that confers a complete drug resistance in a single step can be imposed with a discrete kernel function [50] and a smaller value of w.
Multidrug resistance models parameterized with a binary level of resistance
In this section, we simplify the model given by Eq. 
We scale the drug dosage c(t) to represent the drug effect on the fully-sensitive cells and assume that the fully-resistant cells do not respond to the drug. This yields a drug uptake function for which µ(0) = 1 and µ(1) = 0. Hence, the effect of the cytotoxic drug C(t, θ) = c(t)µ(θ) boils down to
See Table 1 for a summary of the fitness parameters.
parameters biological meaning γ maximum proliferation rate η reduced proliferation due to resistance (selection gradient) c(t) maximum apoptosis rate of sensitive cells due to drug The resulting model can be written as a dynamical system. For instance, we consider a single (M = 1) cytotoxic drug affecting the proliferating cells. There exists two cell states: sensitive cells, n S (t) . = n P (t, θ = 0), and resistant cells,
. In this case, the resulting system iṡ
where, D = dρ(t), and ρ(t) = n S (t) + n R (t). In the case of a single cytostatic drug affecting the proliferating cells, the dynamics followṡ
In case of M drugs, the resulting model will involve 2 M discrete cell state variables.
The binary models (4) and (5) [53] , the thresholds become η and η/(γ − η) for models (4) and (5), respectively.
To connect between models with binary traits and models with continuous traits, we extend the binary models assuming that the proliferation and drug effects are smooth and monotone with respect to θ. This assumption (although may not always hold) makes it possible to classify continuum scenarios and helps in identifying cases in which the continuous traits dynamics is qualitatively different than the corresponding binary models. Since we only consider proliferating cells, the transfer terms to the quiescent cells are removed from
Eq. (1), and we simulate
Starting from the proliferation, we assume that cells that are resistant to cytotoxic drugs use their resources to develop and maintain the drug resistance mechanism [59, 60] , that is, ϕ (θ) < 0. On the domain of θ ∈ [0, 1], the proliferation function R(θ) = ϕ(θ) can be characterized according to its concavity.
We consider three sample cases:
similarly. Assuming that apoptosis decreases with an increased level of resistance, we have µ (θ) < 0. Accordingly, we consider three characteristic cases:
, and µ(θ) = (1 − θ 2 ). The models we consider are summarized in Table 2 and Figure 2 .
concave up linear concave down Table 2 : Classification of the continuous proliferation and drug effect functions depending on the concavity. We consider three cases for both R(θ) = ϕ(θ) and C(θ) = µ(θ)c(t) denoted as case {1, 2, 3} and {i, ii, iii}, respectively.
Differentiating models with binary traits from models with continuous traits
To demonstrate the difference between models that are based on binary traits and continuous-traits models, we compute the trait that achieves the maximal fitness of Eq. (6) under different microenvironment conditions. We denote such trait with the maximal growth rate as
Our choices of R(θ) and C(θ) in Section 2.1 yield nine cases that are presented in the following list 1 . We comment that among the nine cases, six cases resemble the discrete model in a sense that the maximal fitness trait is binary, either fullysensitive or fully-resistant, while three cases allow intermediate trait levels. This demonstrates that in certain circumstances, continuum models are necessary.
We first consider the single cytotoxic drug setup that is comparable to the binary model (4). The results are summarized in Table 3 .
• Case (3,i). The maximal growth rate is achieved at θ M = c(t)/(η + c(t))
This case allows an intermediate maximal fitness trait for any drug dosage
• Case (3,ii). The maximal growth rate is achieved at θ M = c(t)/(2η). This model increases the maximal trait linearly in terms of the drug dosage when c(t) ≤ 2η. For c(t) > 2η, the maximal fitness occurs at θ M = 1.
• Case (3,iii). The maximal growth rate is either achieved at θ M = 0 when c(t) < η, or at θ M = 1 when c(t) > η. Since the phenotype distribution asymptotically converges to a delta function centered at θ = 0 or θ = 1, the overall quality of the solution is similar to the binary-trait model. We also remark that there exists a critical drug dosage at c(t) = η that yields multiple fitness traits.
• Case (2,i). This model is similar to the case (3,ii), but opposite in the sense that the maximal growth rate is achieved at θ M = 0 for c(t) < η/2, and increases as
• Cases (2,ii), (2,iii), (1,i), (1,ii), and (1,iii). These models also yield a solution that is either concentrated at θ M = 0 or θ M = 1, similar to case Table 3 : The selected trait with maximal growth rate θ M = θ M (c, η, γ) depending on the cytotoxic drug concentration c and the resource parameters γ and η.
In addition to cytotoxic drugs, we also consider the drug uptake models in Table 2 for a single cytostatic drug that is comparable to the binary model (5).
The maximal fitness traits for the different choices of proliferation rate functions and drug uptake functions are summarized in Table 4 .
Simulation of continuum model in cytotoxic and cytostatic resistance
In this section, we simulate the model (6) for the cases shown in Table 2 and compare the results with the binary models (4)- (5) . For the numerical simulations, we consider the maximal proliferation rate as γ = 0.66 per day,
where Table 4 : The selected trait with maximal growth rate θ M = θ M (c, η, γ) depending on the cytostatic drug concentration c and the resource parameters γ and η. We remark that θ M are taken as 0 or 1 in cases (2,i) and (3,ii) similar to Table 3 .
corresponding to a cell cycle of approximately 25 hours [61, 62] . We also assume that the reduction in proliferation of the resistant cells is η = 0.132 per day based on the experiments of non-small lung cancer cells exposed to Erlotinib [59] , where the growth rate of resistant cell is reduced by approximately 70%.
Experiments with HL60 leukemic cells exposed to vincristine [63] and calculation in [51] further support this assumption. We assume a logistic growth by D = dρ(t), where the apoptosis constant that represents the average death rate is taken as d = 0.66·10 −8 . This corresponds to a cell capacity of 10 8 [63] assuming a solid tumor of size 1cm 3 prior to angiogenesis [64] and a tumor cell volume 10 −9 ∼ 3 · 10 −8 cm 3 [65, 66] . , respectively. Cases (2,ii) and (1,iii) result in a distribution that is similar to the binary-trait model, either concentrated at the fully sensitive or fully resistant trait (see Table 3 ).
In Figure 3 , we first present the result of the binary-trait model (4) showing that either the fully-resistant or the fully-sensitive cells survive depending on the drug dosage c 1 (t) compared to η = 0.132. The total number of sensitive and resistant cells, n S (t) and n R (t), are plotted in log scale with a constant drug dosage up to time t = 200. We observe that when c 1 = 0 < η, the sensitive cells dominate at t = 200, however, when the drug dosage increases to c 1 ≥ 0.4 > η, the resistant cells dominate. When c 1 = 0.2 > η, but close to η, the resistant cells will eventually dominate.
In contrast, Figure 4 shows the cancer cell density n(t, θ) of the continuoustrait model (6) subject to cytotoxic drug for cases (3,i), (3,ii), (2,i), (2,ii), and
(1,iii). We vary the constant cytotoxic drug dosage from c 1 = 0 to 0. otherwise. These simulations are consistent with Table 3 .
Moreover, we observe that the transition from the sensitive to the resistant trait is faster in cases (3,ii) and (2,i) compared with case (3,i), and even more rapid in cases (2,ii) and (1,iii). In particular, cases (2,ii) and (1,iii) result in a distribution that is either concentrated at the fully sensitive or fully resistant trait with a threshold c 1 = η = 0.132. (4) and continuous model (6) . As the cytotoxic drug is increased, t * ρ is delayed. The total number of cells at ts when the tumor growth slows down is monotonically reduced as the drug dosage increases in the continuum case (3,i), while it is not in the binary model and case (1,iii). In particular, the dynamics is identical in the binary model when the dosage is relatively high as
In addition to the resistance trait density, the following quantities of interest are computed. We denote the time that the tumor size ρ(t) = 5 · 10 7 as
In addition, the full cell capacity is approximately computed as ρ(t s ), where Table 4 ). diate resistance level of maximal fitness is achieved in case (3,i) for all drug dosages c 1 at θ M (c 1 ) = C 1i /2 − C 2 1i /4 − 5, where C 1i = 6 + 1/c 1 , similar to the results of using cytotoxic drugs. We also observe a binary outcome either at the most sensitive or the most resistant trait depending on the drug dosage threshold c 1 = η/(γ − η) = 0.25. The time t * ρ and approximate capacity ρ(t s ) are shown in Figure 8 . In contrast to the cytotoxic drug case, the binary model also shows a gradual change as a function of the drug dosage. Still, the results obtained by the binary and continuous models are different.
Epimutation in drug resistance
In this section, we investigate the effect of epimutation on the drug resistance dynamics of cancer cells. Phenotypic variants in cancer cell populations emerge not only from genetic mutations, but also due to epimutations. Epimutations are heritable changes in gene expression that do not alter the DNA, but contribute to the phenotypic instability [67] [68] [69] [70] [71] . Recent experiments demonstrate that such non-genetic instability and phenotypic variability allows cancer cells to reversibly transit between different phenotypic states [63, 72, 73] and contributes to development of resistance to cytotoxic drugs [75, 76] . In the continuous phenotypic models, epimutation can be readily modeled as a diffusion term assuming that random epimutations yield infinitesimally small phenotypic modifications [51, 77, 78] . The dynamics of proliferating cells in Eq. (6) with an epimutation rate ν can be written as
The asymptotic distribution of the continuum model with epimutation for the case (3,i) is derived in [51] . Here, we study the effect of epimutation in different continuum models. Figure 9 shows the resistance trait density n(t, θ) with epimutation using Eq. (7) corresponding to cases (3,i) and (1,iii) when the rate of epimutation is ν = 10 −2 . Although the maximum fitness trait is similar to the results without epimutations in Figure 4 , the phenotypic instability yields a significantly more heterogeneous population, not only in case (3,i), where the maximal fitness trait is intermediate, but also in case (1,iii), where the distribution becomes a Dirac-delta function at the boundary trait without epimutations.
We now study the effect of epimutations on the time t * ρ that the tumor size reaches a certain size in different models subject to cytotoxic drugs. In Figure   4 , the cell population is significantly more heterogeneous. particular, we compare epimutations with regular mutations. Figure 10 shows the time of relapse using the binary models (4)- (5) with and without mutations of rate w = 10 −2 initiated from n S (0) = 0.99 and n R (0) = 0.01. In general, mutations accelerate the relapse time by increasing the proportion of resistant cells under a sufficiently high dosage. We remark that this is similar in the continuum models, when using the asymmetric mutation kernel M (θ, ϑ) described section 2. However, Figures 11 and 12 show that epimutations in the continuum model (7) often delay the relapse time. We consider two ini- In Figure 11 , using the epimutation model (7) subject to cytotoxic drugs, we observe that t * ρ is delayed with the initial condition n a , especially in case (iii) with a larger rate ν. However, epimutations with initial condition n b accelerate the relapse in case (i), and also for a certain range of drug dosages in case (iii).
For a higher cytotoxic dosage c 1 in case (iii), the relapse time is again delayed.
Similarly, Figure 12 shows the effect of epimutations on the conitnuum model (7) subject to cytostatic drugs. Compared with the cytotoxic drugs, resistance to cytostatic drugs is less affected by epimutation especially when starting with the initial condition n a . However, an earlier relapse is observed with the initial condition n b in both models (i) and (iii). However, an earlier relapse is observed with the initial condition n b .
In conclusion, compared with regular mutations that give advantage to tumor growth under drug administration, epimutations have more diverse effects that can either promote or slow down tumor growth depending on other circumstances, including the drug uptake function and the initial conditions.
Simulating tumor growth under multidrug therapy
In this section we demonstrate how our continuous phenotype structured modeling framework can be used to study MDR. The impact of the tumor's turnover rate and the proliferating fraction of cancer cells have been studied within a discrete phenotype framework by Komarova and Wodarz (2005) [53] and by Gardner (2002) [54] . Here, we compare the results obtained with our approach with the conclusions of [53, 54] .
Multidrug resistance: tumor turnover rate
The impact of the turnover rate in tumor growth and resistance dynamics has been studied by Komarova and Wodarz (2005) [53] . Their model assumes two discrete states for M cytotoxic drugs, adding to 2 M discrete resistance levels. The model assumes a constant growth rate R, a constant death rate D, and is independent of the cell-cycle. Komarova The simulation we present is computed using the continuum model (6) with the different drug response functions in Table 2 . As in [53] , we assume a constant proliferation rate R = 1, and model the high and low turnover tumor by setting D = 0.9 and D = 0.1, respectively. The cytotoxic drug effect is taken as
, where we consider a single parameter c for the drug dosage,
) with the uptake functions µ i (θ). We consider the drug dosages around c(t) ≈ 0.1 in high turnover tumors and c(t) ≈ 0.9 in low turnover tumors. Figure 13 presents the cell density in the resistance trait space using the continuum model (6) subject to a combination therapy using two cytotoxic drugs (M = 2). We consider a high turnover tumor with the uptake functions of cases (i,i), (i,iii), and (iii,iii), and set the drug dosage as c = 0.1, 0.2, 0.4. The distributions shown are cancer cell densities in log scale, log(n(t, θ 1 , θ 2 )), at time We now compare the responses of high and low turnover tumors with respect to the number of drugs M in the continuous models. Figure 14 shows the total number of cells ρ(t) up to t = 100 for an increasing number of drugs M = 1, . . . , 5, and increasing drug dosages. We choose case (i) for the drug uptake function. As expected, we observe a delayed growth with an increased number of drugs and increased dosages. While increasing the number of drugs is not effective in high turnover tumors in the model of [53] , it is effective in the continuum model (6) with the drug update model (i) and high dosages c ≥ 0.2. Figure 15 compares the total number of cells in four different continuum models, combining the drug effect (case (i), (iii)) and the turnover rate (D = 0.9, 0.1).
We observe that increasing the drug dosage over a certain threshold is less likely to delay the relapse time in low turnover tumor for which the drug uptake follows case (iii). It is effective in drug uptake case (i). Finally, Figure 16 shows the effect of increasing the number of drugs assum- We conclude that in addition to the turnover rate, the drug uptake function of the continuum model is also important in controlling the outcome of the treatment. In particular, a combination therapy with multiple drugs is effective not only in low turnover tumors, but also in high turnover tumors with the drug uptake case (i). Moreover, a high cytotoxic drug dosage in low turnover tumor with case (iii) is less effective than case (i). The drug uptake function is often more important than the turnover rate in determining the outcome of the tumor growth and relapse, particularly with a logistic growth condition.
Multidrug resistance: heterogeneity due to the proliferating index
Gardner ( The governing system in [54] assumes three discrete drug resistance levels, θ i = {0, 0.5, 1}, for each of the six drugs, and it is similar to Eqs. (1)- (2):
Here n P and n Q are defined on 3 6 discrete resistance levels. In addition, 
We denote the CS cytotoxic drugs as C 1 and C 2 , the nCS cytotoxic drugs as C 3 and C 4 , and the cytostatic drugs as C 5 and C 6 . The drug effects are modeled using the exponential kill model [81] as C i (θ i ) = R 1 − e −ai(θmax−θi)ci(t) for the CS cytotoxic drug (i = 1, 2), C i (θ i ) = 1 − e −ai(θmax−θi)ci(t) for the nCS cytotoxic drug (i = 3, 4), and C i (θ i ) = z i 1 − e −ai(θmax−θi)ci(t) for the cytostatic drug (i = 5, 6), where θ max = 1 and the domain of resistance trait is taken at three discrete levels θ i ∈ {0, 0.5, 1}. The net drug effects are taken as Figure 17 shows the three discrete levels of drug effect using the dosages c 1 ,
..., c 6 from [54] (see Appendix A). We note that although Gardner considers three levels of resistance, the cells with sensitive levels θ i = 0 and θ i = 0.5 of i = 1, 2, 3, and 6 have similar response to the drug. Moreover, the exponential kill model of C 1 , C 2 , C 3 , and C 6 based on the concavity can be classified as our case (iii), and C 4 and C 5 as case (ii). In the following simulations, we assume that the proliferation R and the drug effects C i in Eqs. (1)- (2) follow the models as in Table 2 with the net drug effect as in (9), and compare the results with the discrete model (8) . See Appendix A for the model parameters. Figure 18 compares the result of the discrete model (8) and the continuum model (1)- (2), in particular with regards to the drug C 2 . Shown is the cell distribution on the resistance trait space of drug C 2 in log scale 2 , when using no drug, a single drug c 2 , and all 6 drugs. Here, the continuum model is taken
as the exponential kill model that can be classified as cases (iii) and (ii). As expected from the shape of the uptake function in Figure 17 , the distribution in the θ 2 trait space is concentrated at the boundary traits, similarly to the discrete model. However, the continuum model predict emerging cells with intermediate levels of resistance, and the degree of heterogeneity in the resistance level can be quantitatively computed. However, the continuum model (1)- (2) shows a more gradual increase of resistance. Moreover, the resistance to nCS cytotoxic drugs develops more rapidly in case (iii) than in case (i). On the other hand, resistance to CS cytotoxic drugs and to cytostatic drugs is more sensitive to the drug application in case (i) that in case (iii). We finally comment that E[Q i (t, θ i )] shows similar dynamics when using drugs with the same mechanism, that is, the results with drugs C 1 , C 3 , and C 5 are similar to C 2 , C 4 , and C 6 , respectively.
Gardner (2002) [54] presents the effect of different drug combinations particularly to cancer cells with different proliferating proportions δ(t). Figure 21 shows simulations of the total number of tumor cells ρ(t) with a highly proliferating index (δ * = 0.5) and a low proliferating index (δ * = 0.05). We demonstrate that the drug response function plays a key role in determining the tumor growth dynamics using certain combination therapies that often involve the nCS cytotoxic drugs (C 3 and C 4 ). In general, the drug combinations that includes CS cytotoxic drugs (C 1 and C 2 ) are more effective in highly proliferating tumors. In the discrete model (8) 
Conclusion
In this paper we propose a mathematical model for multidrug resistance, assuming a continuous resistance phenotype space. The multidrug resistance trait variable represents the level of resistance to various drugs including cellcycle specific and nonspecific cytotoxic drugs, as well as cytostatic drugs. We classify the proliferation and drug uptake functions and identify the cases where the continuum model results in an intermediate maximal fitness resistance, i.e., the cases in which the continuum and discrete models are essentially different.
Thus, by observing the proliferation and drug effects, we can predict when the continuum models are different than the corresponding discrete models. We study the effect of epimutation on the cytotoxic and cytostatic resistance traits.
In contrast to standard mutations that are associated with an early relapse, epimutations may either accelerate or delay the relapse time. We demonstrate such effects on different continuum models, initial preexisting resistance ratios, and types of drugs.
We use our approach to revising the works of Komarova and Wodarz (2005) [53] and the Gardner (2002) [54] . Following [53] , we study the impact of the turnover rate on tumor growth and drug response. We verify the effectiveness of a combination therapy with multiple cytotoxic drugs in low turnover tumors and also in high turnover tumors with a drug uptake function of case (i) under high drug dosages. Increasing the cytotoxic drug dosage delays the relapse in tumor that the drug uptake follows case (iii), but not in low turnover tumor with case (i), thus in particular in such cases, the dosage should be carefully chosen. Moreover, the choice of a drug uptake function is shown to have a higher impact than the turnover rate under a logistic growth condition. These results provide new insights on the dynamics beyond what is accessible by (and in certain cases even contradictory to) the discrete-trait model of [53] .
The second example we studied followed [54] by considering three different types of drugs: cell cycle specific and nonspecific cytotoxic drugs, and cytostatic drugs. We demonstrated that the size of the tumor is more sensitive to the drug dosage in the continuum models compared with the model of [54] . In addition, a drug combination without the cell cycle specific cytotoxic drug shows no disadvantage in highly proliferating tumors in the discrete model, which is not the case in the continuum models. We conclude that the dynamics of the cancer cell population including the time of relapse and the resistance profile significantly depends on the choice of (continuum) models, in addition to the turnover rate and the proliferation index. Thus, it is critical to select appropriate multidrug resistance models depending on the drug response of each individuals, to accomplish an effective individually-tailored cancer modeling framework and a corresponding optimal drug therapy.
Our future work includes deriving a continuum model from high-dimensional data that will be preprocessed with data analysis techniques. In addition, mod-eling the dependency structure of multiple drugs and investigating its effect on the resistance dynamics is another challenging topic. Finally, due to its dimensionality, simulation of multidrug resistance model requires developing an efficient numerical method that balances computational cost and accuracy. This will be addressed with adaptive numerical methods that take advantage of the underlying low dimensional structure of the solution. • Mutation rate: w = 10 −6 [26] .
